Clinical relevancy and risks of potential drug-drug interactions in intensive therapy

Saudi Pharmaceutical Journal

Volumn 23, Issue 4, 2015, Pages 366-370

  Rodrigues, Aline Teotonio ^a   Stahlschmidt, Rebeca ^a   Granja, Silvia ^a   Falcão, Antonio Luis Eiras ^a   Moriel, Patricia ^a   Mazzola, Priscila Gava ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Intensive Care Unit; Potential drug drug interactions; Prescription orders

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; AGENTS AFFECTING METABOLISM; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CYTOCHROME P450 INHIBITOR; DERMATOLOGICAL AGENT; DIGESTIVE TRACT AGENT; HEMATOLOGIC AGENT; HORMONE; IMMUNOMODULATING AGENT; METOCLOPRAMIDE; PRESCRIPTION DRUG; RESPIRATORY TRACT AGENT; SEX HORMONE;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; BRONCHOSPASM; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CENTRAL NERVOUS SYSTEM DISEASE; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INTERACTION; DRUG SAFETY; EVALUATION STUDY; FEMALE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LIFE THREAT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OBSERVATIONAL STUDY; PATIENT MONITORING; PATIENT RISK; PRESCRIPTION; PROSPECTIVE STUDY; RESPIRATION DEPRESSION;

EID: 84942369150     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2014.11.014     Document Type: Article

References (19)

1. Askari M., Eslami S., Louws M., Wierenga P.C., Dongelmans D.A., Kuiper R.A., Abu-Hanna A. Frequency and nature of drug-drug interactions in the intensive care unit. Pharmacopidemiol. Drug Safety 2013, 22:430-437.
2. Blix H.S., Viktil K.K., Moger T.A., Reikvam A. Identification of drug interactions in hospitals - computerized screening vs. bedside recording. J. Clin. Pharm. Therap. 2008, 33:131-139.
3. Chisholm-Burns M., Lee J., Spivey C., Slack M., Herrier R., Hall-Lipsy E., et al. US pharmacists' effect as team members on patient care systematic review and meta-analyses. Medical Care 2010, 48:923-933.
4. Cullen D.J., Sweitzer B.J., Bates D.W., Burdick E., Edmondson A., Leape L.L. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit. Care Med. 1997, 25:1289-1297.
5. David S., Tatro P.D. Drug Interaction Facts 2013: The Authority on Drug Interactions 2012, Publisher: Lippincott Williams & Wilkins.
6. Duan J.Z., Jackson A.J., Zhao P. Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. J. Clin. Pharmacol. 2011, 51:1087-1100.
7. Hasan S.S., Lim K.N., Anwar M., Sathvik B.S., Ahmadi K., Yuan A.W., et al. Impact of pharmacists' intervention on identification and management of drug-drug interactions in an intensive care setting. Singapore Med. J. 2012, 53:526-531.
8. Leape L.L., Cullen D.J., Clapp M.D., Burdick E., Demonaco H.J., Erickson J.I., et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA - J. Am. Med. Assoc. 1999, 282:267-270.
9. Micromedex® Healthcare Series [Internet]. Thomson Reuters. 2011.
10. Papadopoulos J., Smithburger P.L. Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. Crit. Care Med. 2010, 38:S126-S135.
11. Paterno M.D., Maviglia S.M., Gorman P.N., Seger D.L., Yoshida E., Seger A.C., et al. Tiering drug-drug interaction alerts by severity increases compliance rates. J. Am. Med. Inform. Assoc. 2009, 16:40-46.
12. Plaza J., Alamo M., Torres P., Fuentes A., Lopez F. Drug interactions and adverse events induced by drugs used in an intensive care unit. Revista Med. De Chile 2010, 138:452-460.
13. Smithburger P.L., Kane-Gill S.L., Benedict N.J., Falcione B.A., Seybert A.L. Grading the severity of drug-drug interactions in the intensive care unit: a comparison between clinician assessment and proprietary database severity rankings. Ann. Pharmacotherap. 2010, 44:1718-1724.
14. Smithburger P.L., Kane-Gill S.L., Seybert A.L. Drug-drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug Safety 2010, 33:879-888.
15. Smithburger P.L., Buckley M.S., Bejian S., Burenheide K., Kane-Gill S.L. A critical evaluation of clinical decision support for the detection of drug-drug interactions. Exp. Opin. Drug Safety 2011, 10:871-882.
16. Smithburger P.L., Kane-Gill S.L., Seybert A.L. Drug-drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. Int. J. Pharm. Pract. 2012, 20:402-408.
17. Spriet I., Meersseman W., de Hoon J., et al. Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med. 2009, 35:603-612.
18. Uijtendaal E.V.1., van Harssel L.L., Hugenholtz G.W., Kuck E.M., Zwart-van Rijkom J.E., Cremer O.L., Egberts T.C. Analysis of potential drug-drug interactions in medical intensive care unit patients. Pharmacotherapy 2014, 34:213-219.
19. Wright A., Feblowitz J., Phansalkar S., Liu J.L., Wilcox A., Keohane C.A., et al. Preventability of adverse drug events involving multiple drugs using publicly available clinical decision support tools. Am. J. Health-System Pharm. 2012, 69:221-227.